Journal of Antimicrobial Chemotherapy (1999) 43, 645-649
© 1999 The British Society for Antimicrobial Chemotherapy
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents
a Departments of Pathology, Hershey Medical Center, 500 University Drive, Hershey, PA 17033; b Case Western Reserve University, Cleveland, OH 44106, USA
An agar dilution MIC method was used to test the activity of gatifloxacin, a new broad-spectrum fluoroquinolone, compared with ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin, amoxycillin, cefuroxime, ceftriaxone and clarithromycin against 71 penicillin-susceptible, 81 penicillin-intermediate and 55 penicillin-resistant pneumococci. Quinolone activity was unaffected by penicillin susceptibility, with MIC 50/MIC 90s (mg/L) of 0.25/0.5 for gatifloxacin; 1/2 for ciprofloxacin; 1/2 for levofloxacin; 0.25/0.5 for sparfloxacin; 0.125/0.25 for trovafloxacin. ß-Lactam and clarithromycin MICs rose with those of penicillin G; MIC 50/MIC 90 values (mg/L) for penicillin-susceptible, -intermediate and -resistant strains were: 0.03/0.06, 0.25/1, 2/4 for penicillin G; 0.03/0.03, 0.125/1, 2/4 for amoxycillin; 0.03/0.125, 0.5/4, 8/16 for cefuroxime; 0.03/0.03, 0.25/0.5, 2/4 for ceftriaxone; 0.03/0.06, 0.03/>64, 1/>64 for clarithromycin. Time-kill testing of four penicillin-susceptible, four -intermediate and four -resistant strains showed that levofloxacin at the MIC, gatifloxacin and sparfloxacin at 2 x MIC, and trovafloxacin and ciprofloxacin at 4 x MIC, were bactericidal (99.9% killing) for all strains after 12 h and 24 h. By contrast, amoxycillin, cefuroxime and ceftriaxone showed bactericidal activity after 24 h against all strains at 4, 8 and 4 x MIC, respectively. Against ten organisms with clarithromycin MICs of 0.03-4.0 mg/L, clarithromycin was bactericidal against seven strains at 8 x MIC after 24 h. Quinolones showed more rapid killing at lower concentrations and earlier time periods than did ß-lactams and clarithromycin.
* Corresponding author: Tel +1-717-531-5113; Fax +1-717-531-7953; E-mail: pappelbaum{at}psghs.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Kosowska-Shick, L. M. Ednie, P. McGhee, and P. C. Appelbaum Comparative Antipneumococcal Activities of Sulopenem and Other Drugs Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2239 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Clark, K. Smith, L. Ednie, T. Bogdanovich, B. Dewasse, P. McGhee, and P. C. Appelbaum In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci Antimicrob. Agents Chemother., January 1, 2008; 52(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosowska-Shick, K. Credito, G. A. Pankuch, G. Lin, B. Bozdogan, P. McGhee, B. Dewasse, D.-R. Choi, J. M. Ryu, and P. C. Appelbaum Antipneumococcal Activity of DW-224a, a New Quinolone, Compared to Those of Eight Other Agents. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2064 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Browne, B. Bozdogan, C. Clark, L. M. Kelly, L. Ednie, K. Kosowska, B. Dewasse, M. R. Jacobs, and P. C. Appelbaum Antipneumococcal Activity of DK-507k, a New Quinolone, Compared with the Activities of 10 Other Agents Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3815 - 3824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Trampuz, G. Laifer, M. Wenk, Z. Rajacic, and W. Zimmerli Pharmacokinetics and Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Granulocyte-Rich Exudate Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3630 - 3633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ince and D. C. Hooper Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2755 - 2764. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Honeybourne, D. Banerjee, J. Andrews, and R. Wise Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy J. Antimicrob. Chemother., July 1, 2001; 48(1): 63 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Coyle, G. W. Kaatz, and M. J. Rybak Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1654 - 1659. [Abstract] [Full Text]
|
|
|
|
|
|
M. Perrig, F. Acosta, M. Cottagnoud, C. M. Gerber, M. G. Tauber, and P. Cottagnoud Efficacy of gatifloxacin alone and in combination with cefepime against penicillin-resistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro J. Antimicrob. Chemother., May 1, 2001; 47(5): 701 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Fung-Tomc, E. Gradelski, L. Valera, B. Kolek, and D. P. Bonner Comparative Killing Rates of Fluoroquinolones and Cell Wall-Active Agents Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1377 - 1380. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum Postantibiotic Effects of Gatifloxacin against Gram-Positive and -Negative Organisms Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2574 - 2575. [Abstract] [Full Text]
|
|